Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer

• DOI: 10.1016/j.clinsp.2023.100291
• Publication Date: 2023-10-29T00:19:42Z
• Authors: Qi Liu; Lingli Hou; Ying Zhao; Hongwei Yang; Zhengying Mo; Fei Yu
• Keywords: Fulvestrant; Letrozole

This study aimed to compare progression-free survival, overall clinical benefits, and adverse effects in postmenopausal women with hormone receptor-positive HER2-negative breast cancer who received buparlisib plus fulvestrant against those of dalpiciclib fulvestrant, considering ribociclib letrozole treatment as the reference standard.